1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–267. [PMC free article] [PubMed] [Google Scholar]
2. Marquis RE, Whitson JT. Management of glaucoma: Focus on pharmacological therapy. Drugs Aging. 2005;22:1–21. [PubMed] [Google Scholar]
3. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, et al. The ocular hypertension treatment study: Baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714–720. [PubMed] [Google Scholar]
4. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–713. [PubMed] [Google Scholar]
5. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, et al. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–1279. [PubMed] [Google Scholar]
6. Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:1965–1972. [PubMed] [Google Scholar]
7. Francis BA, Alvarado J. The cellular basis of aqueous outflow regulation. Curr Opin Ophthalmol. 1997;8:19–27. [PubMed] [Google Scholar]
8. Rao VP, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs. 2007;21:167–177. [PubMed] [Google Scholar]
9. Gabelt BT, Kaufman PL. Changes in aqueous humor dynamics with age and glaucoma. Prog Retin Eye Res. 2005;24:612–637. [PubMed] [Google Scholar]
10. Lütjen-Drecoll E. Functional morphology of the trabecular meshwork in primate eyes. Prog Retin Eye Res. 1999;18:91–119. [PubMed] [Google Scholar]
11. Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res. 1994;59:723–727. [PubMed] [Google Scholar]
12. Wiederholt M, Thieme H, Stumpff F. The regulation of trabecular meshwork and ciliary muscle contractility. Prog Retin Eye Res. 2000;19:271–295. [PubMed] [Google Scholar]
13. Yorio T, Krishnamoorthy R, Prasanna G. Endothelin: Is it a contributor to glaucoma pathophysiology? J Glaucoma. 2002;11:259–270. [PubMed] [Google Scholar]
14. Tezel G, Kass MA, Kolker AE, Becker B, Wax MB. Plasma and aqueous humor endothelin levels in primary open-angle glaucoma. J Glaucoma. 1997;6:83–89. [PubMed] [Google Scholar]
15. Lütjen-Drecoll E. Morphological changes in glaucomatous eyes and the role of TGFbeta2 for the pathogenesis of the disease. Exp Eye Res. 2005;81:1–4. [PubMed] [Google Scholar]
16. Challa P, Arnold JJ. Rho-kinase inhibitors offer a new approach in the treatment of glaucoma. Expert Opin Investig Drugs. 2014;23:81–95. [PubMed] [Google Scholar]
17. Wang H, Cheng JW, Wei RL, Cai JP, Li Y, Ma XY. Meta-analysis of selective laser trabeculoplasty with argon laser trabeculoplasty in the treatment of open-angle glaucoma. Can J Ophthalmol. 2013;48:186–192. [PubMed] [Google Scholar]
18. Brusini P. Canaloplasty in open-angle glaucoma surgery: A four-year follow-up. ScientificWorldJournal 2014. 2014 469609. [PMC free article] [PubMed] [Google Scholar]
19. Brandão LM, Grieshaber MC. Update on minimally invasive glaucoma surgery (MIGS) and new implants. J Ophthalmol 2013. 2013 705915. [PMC free article] [PubMed] [Google Scholar]
20. Voskanyan L, García-Feijoó J, Belda JI, Fea A, Jünemann A, Baudouin C, et al. Prospective, unmasked evaluation of the iStent® inject system for open-angle glaucoma: Synergy trial. Adv Ther. 2014;31:189–201. [PMC free article] [PubMed] [Google Scholar]
21. Hays CL, Gulati V, Fan S, Samuelson TW, Ahmed II, Toris CB. Improvement in outflow facility by two novel microinvasive glaucoma surgery implants. Invest Ophthalmol Vis Sci. 2014;55:1893–1900. [PMC free article] [PubMed] [Google Scholar]
22. Jordan JF, Wecker T, van Oterendorp C, Anton A, Reinhard T, Boehringer D, et al. Trabectome surgery for primary and secondary open angle glaucomas. Graefes Arch Clin Exp Ophthalmol. 2013;251:2753–2760. [PMC free article] [PubMed] [Google Scholar]
23. Wilmsmeyer S, Philippin H, Funk J. Excimer laser trabeculotomy: A new, minimally invasive procedure for patients with glaucoma. Graefes Arch Clin Exp Ophthalmol. 2006;244:670–676. [PubMed] [Google Scholar]
24. Inoue T, Tanihara H. Rho-associated kinase inhibitors: A novel glaucoma therapy. Prog Retin Eye Res. 2013;37:1–12. [PubMed] [Google Scholar]
25. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: Modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev. 2003;83:1325–1358. [PubMed] [Google Scholar]
26. Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci. 2001;22:32–39. [PubMed] [Google Scholar]
27. Wettschureck N, Offermanns S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med (Berl) 2002;80:629–638. [PubMed] [Google Scholar]
28. Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y, et al. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science. 1997;275:1308–1311. [PubMed] [Google Scholar]
29. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990–994. [PubMed] [Google Scholar]
30. Rao MY, Soliman H, Bankar G, Lin G, MacLeod KM. Contribution of Rho kinase to blood pressure elevation and vasoconstrictor responsiveness in type 2 diabetic Goto-Kakizaki rats. J Hypertens. 2013;31:1160–1169. [PubMed] [Google Scholar]
31. Li Y, Zhu W, Tao J, Xin P, Liu M, Li J, et al. Fasudil protects the heart against ischemia-reperfusion injury by attenuating endoplasmic reticulum stress and modulating SERCA activity: The differential role for PI3K/Akt and JAK2/STAT3 signaling pathways. PLoS One. 2012;7:e48115. [PMC free article] [PubMed] [Google Scholar]
32. Li Q, Xu Y, Li X, Guo Y, Liu G. Inhibition of Rho-kinase ameliorates myocardial remodeling and fibrosis in pressure overload and myocardial infarction: Role of TGF-ß1-TAK1. Toxicol Lett. 2012;211:91–97. [PubMed] [Google Scholar]
33. Hallgren O, Rolandsson S, Andersson-Sjöland A, Nihlberg K, Wieslander E, Kvist-Reimer M, et al. Enhanced ROCK1 dependent contractility in fibroblast from chronic obstructive pulmonary disease patients. J Transl Med. 2012;10:171. [PMC free article] [PubMed] [Google Scholar]
34. Aihara M, Dobashi K, Iizuka K, Nakazawa T, Mori M. Effect of Y-27632 on release of cytokines from peripheral T cells in asthmatic patients and normal subjects. Int Immunopharmacol. 2004;4:557–561. [PubMed] [Google Scholar]
35. Wei B, Shang YX, Li M, Jiang J, Zhang H. Cytoskeleton changes of airway smooth muscle cells in juvenile rats with airway remodeling in asthma and the RhoA/ROCK signaling pathway mechanism. Genet Mol Res. 2014;13:559–569. [PubMed] [Google Scholar]
36. Mishra RK, Alokam R, Sriram D, Yogeeswari P. Potential role of Rho kinase inhibitors in combating diabetes-related complications including diabetic neuropathy: A review. Curr Diabetes Rev. 2013;9:249–266. [PubMed] [Google Scholar]
37. Teixeira CE, Ying Z, Webb RC. Proerectile effects of the Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinolinyl) sulfonyl] homopiperazine (H-1152) in the rat penis. J Pharmacol Exp Ther. 2005;315:155–162. [PubMed] [Google Scholar]
38. Sanka K, Maddala R, Epstein DL, Rao PV. Influence of actin cytoskeletal integrity on matrix metalloproteinase-2 activation in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2007;48:2105–2114. [PubMed] [Google Scholar]
39. Rikitake Y, Kim HH, Huang Z, Seto M, Yano K, Asano T, et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke. 2005;36:2251–2257. [PMC free article] [PubMed] [Google Scholar]
40. Gottanka J, Kuhlmann A, Scholz M, Johnson DH, Lütjen-Drecoll E. Pathophysiologic changes in the optic nerves of eyes with primary open angle and pseudoexfoliation glaucoma. Invest Ophthalmol Vis Sci. 2005;46:4170–4181. [PubMed] [Google Scholar]
41. Honjo M, Tanihara H, Kameda T, Kawaji T, Yoshimura N, Araie M. Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2007;48:5549–5557. [PubMed] [Google Scholar]
42. Tanihara H, Inatani M, Honjo M, Tokushige H, Azuma J, Araie M. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol. 2008;126:309–315. [PubMed] [Google Scholar]
43. Williams RD, Novack GD, van Haarlem T, Kopczynski C AR-12286 Phase 2A Study Group. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol. 2011;152:834–41.e1. [PubMed] [Google Scholar]
44. Arnold JJ, Hansen MS, Gorman GS, Inoue T, Rao V, Spellen S, et al. The effect of Rho-associated kinase inhibition on the ocular penetration of timolol maleate. Invest Ophthalmol Vis Sci. 2013;54:1118–1126. [PMC free article] [PubMed] [Google Scholar]
45. Tokushige H, Inatani M, Nemoto S, Sakaki H, Katayama K, Uehata M, et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2007;48:3216–3222. [PubMed] [Google Scholar]
46. Shimizu Y, Thumkeo D, Keel J, Ishizaki T, Oshima H, Oshima M, et al. ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol. 2005;168:941–953. [PMC free article] [PubMed] [Google Scholar]
47. Okumura N, Koizumi N, Kay EP, Ueno M, Sakamoto Y, Nakamura S, et al. The ROCK inhibitor eye drop accelerates corneal endothelium wound healing. Invest Ophthalmol Vis Sci. 2013;54:2493–2502. [PubMed] [Google Scholar]
48. Pipparelli A, Arsenijevic Y, Thuret G, Gain P, Nicolas M, Majo F. ROCK inhibitor enhances adhesion and wound healing of human corneal endothelial cells. PLoS One. 2013;8:e62095. [PMC free article] [PubMed] [Google Scholar]
49. Okumura N, Koizumi N, Ueno M, Sakamoto Y, Takahashi H, Tsuchiya H, et al. ROCK inhibitor converts corneal endothelial cells into a phenotype capable of regenerating in vivo endothelial tissue. Am J Pathol. 2012;181:268–277. [PubMed] [Google Scholar]
50. Okumura N, Nakano S, Kay EP, Numata R, Ota A, Sowa Y, et al. Involvement of cyclin D and p27 in cell proliferation mediated by ROCK inhibitors Y-27632 and Y-39983 during corneal endothelium wound healing. Invest Ophthalmol Vis Sci. 2014;55:318–329. [PubMed] [Google Scholar]
51. Waki M, Yoshida Y, Oka T, Azuma M. Reduction of intraocular pressure by topical administration of an inhibitor of the Rho-associated protein kinase. Curr Eye Res. 2001;22:470–474. [PubMed] [Google Scholar]
52. Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci. 2001;42:1029–1037. [PubMed] [Google Scholar]
53. Honjo M, Tanihara H, Inatani M, Kido N, Sawamura T, Yue BY, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42:137–144. [PubMed] [Google Scholar]
54. Gong H, Yang CY. Morphological and hydrodynamic correlations with increasing outflow facility by rho-kinase inhibitor Y-27632. J Ocul Pharmacol Ther. 2014;30:143–153. [PMC free article] [PubMed] [Google Scholar]
55. Lu Z, Overby DR, Scott PA, Freddo TF, Gong H. The mechanism of increasing outflow facility by rho-kinase inhibition with Y-27632 in bovine eyes. Exp Eye Res. 2008;86:271–281. [PMC free article] [PubMed] [Google Scholar]
56. Rosenthal R, Choritz L, Schlott S, Bechrakis NE, Jaroszewski J, Wiederholt M, et al. Effects of ML-7 and Y-27632 on carbachol- and endothelin-1-induced contraction of bovine trabecular meshwork. Exp Eye Res. 2005;80:837–845. [PubMed] [Google Scholar]
57. Tokushige H, Waki M, Takayama Y, Tanihara H. Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats. Curr Eye Res. 2011;36:964–970. [PubMed] [Google Scholar]
58. Nishio M, Fukunaga T, Sugimoto M, Ikesugi K, Sumi K, Hidaka H, et al. The effect of the H-1152P, a potent Rho-associated coiled coil-formed protein kinase inhibitor, in rabbit normal and ocular hypertensive eyes. Curr Eye Res. 2009;34:282–286. [PubMed] [Google Scholar]
59. Sumi K, Inoue Y, Nishio M, Naito Y, Hosoya T, Suzuki M, et al. IOP-lowering effect of isoquinoline-5-sulfonamide compounds in ocular normotensive monkeys. Bioorg Med Chem Lett. 2014;24:831–834. [PubMed] [Google Scholar]
60. Van de Velde S, Van Bergen T, Sijnave D, Hollanders K, Castermans K, Defert O, et al. AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci. 2014;55:1006–1016. [PubMed] [Google Scholar]
61. Fukunaga T, Ikesugi K, Nishio M, Sugimoto M, Sasoh M, Hidaka H, et al. The effect of the Rho-associated protein kinase inhibitor, HA-1077, in the rabbit ocular hypertension model induced by water loading. Curr Eye Res. 2009;34:42–47. [PubMed] [Google Scholar]
62. Honjo M, Inatani M, Kido N, Sawamura T, Yue BY, Honda Y, et al. Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes. Arch Ophthalmol. 2001;119:1171–1178. [PubMed] [Google Scholar]
63. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M, et al. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156:731–736. [PubMed] [Google Scholar]
64. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M, et al. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol. 2013;131:1288–1295. [PubMed] [Google Scholar]
